[1] G. Goldstein, M. Scheid, U. Hammerling, D. Schlesinger, H. Niall and E. Boyse, “Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 72,No. 1, 11–5, 1975.
[2] R. Sujashvili, “Advantages of extracellular ubiquitin in modulation of immune responses,” Mediators of Inflammation, 4190390, 2016.
[3] N. Swatek and D. Komander, “Ubiquitin modifications,” Cell Research, 26, 4, 399–422, 2016.
[4] L. Herhaus, and I. Dikic, “Expanding the ubiquitin code through post-translational modification,” EMBO reports, 16, 9, 1071-83, 2015.
[5] M. Mansour, “Ubiquitination: Friend and foe in cancer,” Int. J. Biochem. Cell Biol. 2018; 101, 80–93, 2018.
[6] J. Harrigan, X. Jacq, N. Martin, S. Jackson, “Deubiquitylating enzymes and drug discovery: Emerging opportunities,” Nat. Rev. Drug Discovery, 2018, 17, 57–78, 2018.
[7] S. Sane, and K. Rezvani, “Essential roles of E3 ubiquitin ligases in p53 regulation,” International Journal of Molecular Sciences, 18, 2, 442, 2017.
[8] K. Takada, H. Nasu, N. Hibi, Y. Tsukada, K. Ohkawa, M. Fujimuro, H. Yokosawa, “Immunoassay for the quantification of intracellular multi-ubiquitin chains,” European Journal of Biochemistry, 233, 1, 42–47, 1995.
[9] S. Rossi, C. Gesualdo, R. Maisto, C. Trotta, N. Di Carluccio, A. Brigida, C. Di Filippo, “High levels of serum ubiquitin and proteasome in a case of HLA-B27 uveitis,” International journal of molecular sciences, 18, 3, 505, 2017.
[10] J. Salazar, “Overview of urea and creatinine,” Laboratory Medicine, Vol. 45, Issue 1, e19–e20, 2014.
[11] E .Torres da Costa, V .Silva, E. C. Costalonga, F. O .Coelho, R. A. Caires, E. A. Burdmann, “Assessment of kidney function in patients with cancer,” Adv Chronic Kidney Dis. 25, 1, 49–56, 2018.
[12] M. Okada, S. Miyazaki, Y. Hirasawa, “Increase in plasma concentration of ubiquitin in dialysis patients: possible involvement in β2-microglobulin amyloidosis,” Clin Chim Acta. 220, 135-144, 1993.
[13] Y. Tang, Y. Geng, J. Luo, W. Shen, W. Zhu, C. Meng, M. Li, X. Zhou, S. Zhang, J. Cao, “Downregulation of ubiquitin inhibits the proliferation and radio resistance of non-small cell lung cancer cells in vitro and in vivo,” Scientific reports, 5, 9476, 2015.
[14] C. Oh, S. Park, K. Lee, and J. Yoo, “Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention,” Scientific reports, 3, 2623, 2013.
[15] L. Haakonsen, and M. Rape, “Ubiquitin levels: the next target against gynecological cancers?,” The Journal of clinical investigation, 127, 12, 4228–4230, 2017.
[16] Y. Liu, Z. Yang, F. Du, Q. Yang, J. Hou and H. Wang, “Molecular mechanisms of pathogenesis in hepatocellular carcinoma revealed by RNA sequencing,” Molecular Medicine Reports, 16, 5, 6674–6682, 2017.
[17] D. Hoeller, I. Dikic, “Targeting the ubiquitin system in cancer therapy,” Nature. 458, 7237, 438–444, 2009.
[18] W. Ma, H. Kantarjian, X. Zhang, X. Wang, Z. Estrov, S. O'Brien and M. Albitar, “Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance,” Leukemia Res., 35, 4, 526-33, 2010.